argenx SE (NASDAQ:ARGX – Get Free Report) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 1,960,000 shares, a growth of 10.7% from the July 15th total of 1,770,000 shares. Based on an average daily trading volume, of 361,700 shares, the short-interest ratio is presently 5.4 days.
argenx Trading Up 0.0 %
Shares of NASDAQ:ARGX traded up $0.10 during trading on Friday, reaching $525.00. The stock had a trading volume of 186,765 shares, compared to its average volume of 330,512. argenx has a one year low of $327.73 and a one year high of $540.49. The company has a market capitalization of $31.20 billion, a P/E ratio of -92.76 and a beta of 0.64. The firm’s 50-day simple moving average is $458.67 and its 200 day simple moving average is $409.17.
argenx (NASDAQ:ARGX – Get Free Report) last released its earnings results on Thursday, July 25th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. The company had revenue of $489.43 million during the quarter, compared to analysts’ expectations of $436.66 million. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. During the same period last year, the business earned ($1.69) EPS. Equities research analysts forecast that argenx will post -0.48 earnings per share for the current fiscal year.
Hedge Funds Weigh In On argenx
Analysts Set New Price Targets
Several analysts have commented on the company. Deutsche Bank Aktiengesellschaft upgraded argenx from a “hold” rating to a “buy” rating in a research note on Thursday, July 25th. Oppenheimer upgraded argenx from a “market perform” rating to an “outperform” rating and set a $546.00 target price on the stock in a research note on Tuesday, July 23rd. Evercore ISI raised their price target on argenx from $478.00 to $533.00 and gave the stock an “outperform” rating in a research note on Friday, July 12th. JPMorgan Chase & Co. reduced their price objective on argenx from $560.00 to $500.00 and set an “overweight” rating for the company in a research report on Monday, May 13th. Finally, William Blair reissued a “market perform” rating on shares of argenx in a report on Monday, June 17th. Three investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $540.37.
Read Our Latest Stock Report on ARGX
About argenx
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Articles
- Five stocks we like better than argenx
- What Are Dividend Champions? How to Invest in the Champions
- This Small Cap Wealth Management Stock Could Provide Big Returns
- When to Sell a Stock for Profit or Loss
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- What is the Nikkei 225 index?
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.